Shares of Misonix, Inc. (NASDAQ:MSON) have received an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 1-year consensus target price of $26.00 for the company, according to Zacks. Zacks has also given Misonix an industry rank of 111 out of 256 based on the ratings given to its competitors.

Separately, TheStreet raised shares of Misonix from a “d” rating to a “c-” rating in a research report on Thursday, February 7th.

Misonix stock traded up $0.43 during midday trading on Wednesday, hitting $19.42. 35,352 shares of the company’s stock were exchanged, compared to its average volume of 43,645. Misonix has a 12-month low of $11.51 and a 12-month high of $21.45.

Misonix (NASDAQ:MSON) last issued its quarterly earnings data on Wednesday, May 8th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.01. Misonix had a negative net margin of 18.10% and a negative return on equity of 29.13%. The company had revenue of $9.56 million for the quarter.

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC boosted its holdings in shares of Misonix by 10.8% in the third quarter. Renaissance Technologies LLC now owns 231,899 shares of the medical equipment provider’s stock valued at $4,290,000 after acquiring an additional 22,599 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Misonix by 15.7% in the third quarter. Vanguard Group Inc. now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after acquiring an additional 28,889 shares in the last quarter. Vanguard Group Inc boosted its holdings in shares of Misonix by 15.7% in the third quarter. Vanguard Group Inc now owns 213,040 shares of the medical equipment provider’s stock valued at $3,941,000 after acquiring an additional 28,889 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of Misonix in the first quarter valued at about $1,688,000. Finally, Northern Trust Corp boosted its holdings in shares of Misonix by 12.1% in the first quarter. Northern Trust Corp now owns 45,878 shares of the medical equipment provider’s stock valued at $882,000 after acquiring an additional 4,952 shares in the last quarter. 18.47% of the stock is currently owned by institutional investors and hedge funds.

About Misonix

Misonix, Inc, together with its subsidiaries, designs, develops, manufactures, and markets therapeutic ultrasonic medical devices in the United States, the Americas, Europe, Middle East, Asia Pacific, Africa, and internationally. The company offers BoneScalpel, an ultrasonic bone cutting and sculpting system for surgical procedures involving the precise cutting of bone while sparing soft tissue; SonaStar, a surgical aspirator that is used to emulsify and remove soft and hard tumors primarily in the neuro and general surgery field; and SonicOne, an ultrasonic cleansing and debridement system, which provides tissue specific debridement and cleansing of wounds and burns for the removal of devitalized tissue and fibrin deposits while sparing viable cells.

Featured Story: What are the qualifications of a portfolio manager?

Get a free copy of the Zacks research report on Misonix (MSON)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Misonix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Misonix and related companies with MarketBeat.com's FREE daily email newsletter.